IFP Advisors Inc Reduces Stock Holdings in Johnson & Johnson $JNJ

IFP Advisors Inc decreased its stake in Johnson & Johnson (NYSE:JNJ) by 4.6% in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 31,788 shares of the company’s stock after selling 1,543 shares during the quarter. IFP Advisors Inc’s holdings in Johnson & Johnson were worth $4,855,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of JNJ. Nuveen LLC purchased a new position in Johnson & Johnson during the 1st quarter valued at $1,369,188,000. Bank of New York Mellon Corp boosted its holdings in Johnson & Johnson by 26.4% during the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company’s stock valued at $3,844,580,000 after acquiring an additional 4,842,582 shares during the period. Pacer Advisors Inc. boosted its holdings in Johnson & Johnson by 1,382.0% during the 1st quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company’s stock valued at $502,509,000 after acquiring an additional 2,825,626 shares during the period. Assenagon Asset Management S.A. boosted its holdings in Johnson & Johnson by 159.6% during the 2nd quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company’s stock valued at $635,327,000 after acquiring an additional 2,557,388 shares during the period. Finally, Kingstone Capital Partners Texas LLC purchased a new position in Johnson & Johnson during the 2nd quarter valued at $401,420,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on JNJ. Bank of America boosted their price objective on Johnson & Johnson from $175.00 to $198.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Erste Group Bank upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Wednesday, July 23rd. Wall Street Zen raised Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Citigroup lifted their target price on Johnson & Johnson from $200.00 to $213.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and set a $209.00 target price on shares of Johnson & Johnson in a research report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $192.94.

Johnson & Johnson Trading Down 0.2%

JNJ opened at $190.66 on Friday. The firm has a market cap of $459.16 billion, a price-to-earnings ratio of 20.39, a PEG ratio of 2.40 and a beta of 0.40. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $192.10. The stock has a fifty day moving average price of $178.48 and a 200-day moving average price of $163.77.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The firm had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were given a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s payout ratio is presently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.